Northern Trust Corp Sells 37,045 Shares of Vaxcyte, Inc. $PCVX

Northern Trust Corp reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 3.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,122,956 shares of the company’s stock after selling 37,045 shares during the quarter. Northern Trust Corp owned about 0.87% of Vaxcyte worth $42,403,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Parallel Advisors LLC lifted its position in Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock valued at $61,000 after acquiring an additional 1,071 shares in the last quarter. IFP Advisors Inc lifted its position in Vaxcyte by 376.4% in the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after acquiring an additional 1,306 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Vaxcyte in the 4th quarter valued at approximately $214,000. Nisa Investment Advisors LLC lifted its position in Vaxcyte by 10.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company’s stock valued at $112,000 after acquiring an additional 293 shares in the last quarter. Finally, Forum Financial Management LP bought a new position in Vaxcyte in the 4th quarter valued at approximately $255,000. 96.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $136.50.

Vaxcyte Trading Up 0.7%

Shares of PCVX opened at $30.77 on Friday. The firm has a market cap of $3.99 billion, a PE ratio of -7.49 and a beta of 1.21. The firm has a fifty day simple moving average of $33.38 and a two-hundred day simple moving average of $43.13. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.10). During the same quarter last year, the firm posted ($1.10) EPS. As a group, research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.